Omnicell, Inc. (NASDAQ:OMCL) Shares Acquired by Stephens Inc. AR

Stephens Inc. AR increased its position in shares of Omnicell, Inc. (NASDAQ:OMCLGet Rating) by 15.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,861 shares of the company’s stock after buying an additional 520 shares during the quarter. Stephens Inc. AR’s holdings in Omnicell were worth $336,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Wipfli Financial Advisors LLC purchased a new stake in Omnicell in the third quarter valued at approximately $25,000. Money Concepts Capital Corp purchased a new stake in Omnicell in the third quarter valued at approximately $27,000. Van ECK Associates Corp purchased a new stake in Omnicell in the third quarter valued at approximately $49,000. Archer Investment Corp raised its position in Omnicell by 27.1% in the second quarter. Archer Investment Corp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 100 shares during the period. Finally, UMB Bank n.a. raised its position in Omnicell by 28.5% in the third quarter. UMB Bank n.a. now owns 721 shares of the company’s stock valued at $63,000 after purchasing an additional 160 shares during the period.

Insider Buying and Selling

In other Omnicell news, EVP Scott Peter Seidelmann sold 4,436 shares of the company’s stock in a transaction on Friday, December 16th. The shares were sold at an average price of $47.79, for a total value of $211,996.44. Following the completion of the transaction, the executive vice president now owns 30,733 shares in the company, valued at $1,468,730.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Omnicell news, EVP Scott Peter Seidelmann sold 4,436 shares of the company’s stock in a transaction on Friday, December 16th. The shares were sold at an average price of $47.79, for a total value of $211,996.44. Following the completion of the transaction, the executive vice president now owns 30,733 shares in the company, valued at $1,468,730.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Randall A. Lipps sold 2,500 shares of the company’s stock in a transaction on Thursday, December 1st. The shares were sold at an average price of $50.78, for a total transaction of $126,950.00. Following the completion of the transaction, the chief executive officer now owns 88,348 shares of the company’s stock, valued at approximately $4,486,311.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,674 shares of company stock worth $476,839. Corporate insiders own 2.76% of the company’s stock.

Omnicell Stock Performance

Shares of OMCL stock opened at $57.81 on Tuesday. The company has a current ratio of 2.25, a quick ratio of 1.86 and a debt-to-equity ratio of 0.50. The firm has a fifty day moving average price of $51.36 and a 200 day moving average price of $78.28. The company has a market cap of $2.56 billion, a P/E ratio of 56.68, a PEG ratio of 5.05 and a beta of 0.89. Omnicell, Inc. has a 12 month low of $46.11 and a 12 month high of $159.57.

Omnicell (NASDAQ:OMCLGet Rating) last issued its earnings results on Wednesday, November 2nd. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.04. The firm had revenue of $348.06 million during the quarter, compared to the consensus estimate of $362.72 million. Omnicell had a net margin of 3.67% and a return on equity of 9.74%. Sell-side analysts predict that Omnicell, Inc. will post 1.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

OMCL has been the topic of a number of research analyst reports. Piper Sandler cut their target price on Omnicell to $55.00 in a research report on Wednesday, December 14th. Craig Hallum cut their target price on Omnicell from $185.00 to $75.00 in a research report on Thursday, November 3rd. Wells Fargo & Company dropped their price target on shares of Omnicell from $158.00 to $71.00 and set an “overweight” rating for the company in a research note on Friday, November 4th. Benchmark downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, November 3rd. Finally, KeyCorp dropped their price target on shares of Omnicell from $130.00 to $75.00 and set an “overweight” rating for the company in a research note on Thursday, November 3rd. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $82.11.

Omnicell Company Profile

(Get Rating)

Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.

Recommended Stories

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.